Instil Bio, Inc. (TIL) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$7.11

From 52W high−66.40%

Volume27516.00

Market cap$48.08M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

$7.11

From 52W high

−66.40%

Volume

27516.00

Market cap

$48.08M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

0.6x

P/E (TTM)

—

RSI (14)

41.5

MomentumView details →

1D Return

−1.66%

YTD Return

−34.27%

SummaryUpdated Jun 1, 2026

Instil Bio, Inc. (NASDAQ:TIL) is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Dallas, Texas. The company went public in March 2021 and focuses on developing innovative cell therapies for cancer treatment. Instil Bio specializes in tumor infiltrating lymphocyte (TIL) therapy, a form of immunotherapy that harnesses the body's own immune system to fight cancer. As a clinical-stage company, Instil Bio has no approved products on the market and is currently conducting clinical trials to demonstrate the safety and efficacy of its therapeutic candidates.

Ask drillr about Instil Bio, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

0.6x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

0.4x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−28.20%

ROA (TTM)

−15.32%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+65.40%

FCF YoY

+52.47%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+6.06%

EBITDA YoY

+60.68%

MomentumView details →

1D Return

−1.66%

YTD Return

−34.27%

1Y Return

−63.72%

RSI (14)

41.5

vs 50D SMA

−2.71%

vs 200D SMA

−12.17%

Capital & dividendView details →

Debt/Equity

0.03x

Current Ratio

21.67x

Quick Ratio

21.67x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.63

EPS Surprise

−80.00%

Beats (12Q)

5/12

Next Q EPS Est

−$0.17

Avg Surprise (4Q)

−8.22%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−30.28M

Op. CF (TTM)

−23.61M

Next earningsNov 16, 2026 →

Latest newsMore news →

Instil Bio reported a Q2 2026 net loss of $4.3 million, or $0.63 per diluted share, with total cash, cash equivalents, restricted cash and marketable securities of $69.9 million as of June 30, 2026, expected to fund operations beyond 2027.39d ago

Similar companies

Werewolf Therapeutics, Inc.HOWL Annovis Bio, Inc.ANVS Mereo BioPharma Group plcMREO Elicio Therapeutics, Inc.ELTX Tevogen Bio Holdings Inc.TVGN Grace Therapeutics, Inc.GRCE Find similar companies →

Latest newsMore news →